Olsetan 20 mg Tablets (Olmesartan Medoxomil)
Olmesartan Medoxomil 20mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
MFDS item code 201100830 · Approved 2011.02.22
This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension
Used to control blood pressure within normal ranges to reduce the risk of cardiovascular diseases. This medication stabilizes blood pressure with regular use and helps prevent complications. It is effective when taken with regular blood pressure monitoring.
<Adults> The recommended initial dose is 10mg once daily, administered with or without food. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. <Elderly patients> No dose adjustment is necessary when administering this medicine to elderly patients aged 65 years or older. <Patients with renal impairment> The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 20-60mL/min) is 20mg once daily. <Patients with hepatic impairment> No dose adjustment is necessary for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, and the dose may be increased to a maximum of 20mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients.
<Pediatric> Safety and efficacy in children have not been established.
This medication can cause serious harm or even death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to any ingredients in this medication, as well as pregnant women, nursing mothers, patients receiving kidney dialysis, patients with severe liver dysfunction, and patients with bile duct obstruction should not take this medication. Patients with reduced blood volume or decreased sodium may experience symptoms of hypotension when starting treatment, so careful monitoring of blood pressure and condition is necessary. Since this medication can affect kidney function, patients with impaired kidney function should regularly have blood tests to check their kidney status. Due to the risk of hyperkalemia, especially those with heart diseases or kidney diseases should periodically check their serum potassium levels. Dizziness may occur during the use of this medication, so caution should be exercised when performing hazardous tasks such as working at heights or driving. This medication shows similar tolerability to placebo, but may have mild side effects such as dizziness, headache, back pain, and dyspepsia. If chronic diarrhea or severe weight loss occurs, discontinue the medication and consult a physician. Interactions may occur if taken with potassium-sparing diuretics, potassium supplements, lithium, non-steroidal anti-inflammatory drugs, etc., so it is essential to consult healthcare professionals when taking this medication with others. Pregnant women should avoid using this medication as it may cause serious abnormalities in the fetus, and nursing mothers should also discontinue breastfeeding or the medication as it may affect the infant. Safety and efficacy in pediatric patients have not been established, so it is best not to administer it to children. In case of overdose, symptoms may include hypotension, palpitations, bradycardia, so if overdose is suspected, visit a medical institution immediately. No carcinogenic risk has been reported with long-term use of this medication, but caution should be exercised.
Dizziness
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is best to maintain a storage temperature between 1 and 25 degrees Celsius to preserve its effectiveness for a long time.
White round film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Olmesartan Medoxomil 20mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

Olmesartan Medoxomil 40mg
Tablet · Prescription medication
JW Pharmaceutical Corp.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
DongKook Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.